{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:29:16Z","timestamp":1787905756094,"version":"build-2784847793"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the safety profile of antegrade mitomycin gel instillation through a percutaneous nephrostomy tube (PCNT) for upper tract urothelial carcinoma (UTUC) with the aim of decreasing morbidity associated with therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Patients undergoing antegrade administration of mitomycin gel via PCNT were retrospectively included for analysis from four tertiary referral centres between 2020 and 2022. The primary outcome was safety profile, as graded by Common Terminology Criteria for Adverse Events (v5.0). Post\u2010therapy disease burden was assessed by primary disease evaluation (PDE) via ureteroscopy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty\u2010two patients received at least one dose of mitomycin gel via PCNT for UTUC, 29 of whom completed induction and underwent PDE. Thirteen patients (41%) had residual tumour present prior to induction therapy. At a median of 15.0\u00a0months following first dose of induction therapy, ureteric stenosis occurred in three patients (9%), all of whom were treated without later recurrence or chronic stenosis. Other adverse events included fatigue (27%), flank pain (19%), urinary tract infection (12%), sepsis (8%) and haematuria (8%). No patients had impaired renal function during follow\u2010up and there were no treatment\u2010related deaths. Seventeen patients (59%) had no evidence of disease at PDE and have not experienced recurrence at a median follow\u2010up of 13.0\u00a0months post induction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Administration of mitomycin gel via a PCNT offers a low rate of ureteric stenosis, demonstrates a favourable safety profile, and is administered without general anaesthesia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.15925","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T05:10:11Z","timestamp":1666761011000},"page":"471-476","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antegrade administration of mitomycin gel for upper tract urothelial carcinoma\n                    <i>via<\/i>\n                    percutaneous nephrostomy tube: a\n                    <scp>multi\u2010institutional<\/scp>\n                    retrospective cohort study"],"prefix":"10.1111","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7728-1144","authenticated-orcid":false,"given":"Kyle M.","family":"Rose","sequence":"first","affiliation":[{"name":"Department of Genitourinary Oncology H. Lee Moffitt Cancer Center  Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0626-8994","authenticated-orcid":false,"given":"Gopal","family":"Narang","sequence":"additional","affiliation":[{"name":"Department of Urology Mayo Clinic Arizona  Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Rosen","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery University of Missouri  Columbia MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Labatte","sequence":"additional","affiliation":[{"name":"Department of Urologic Oncology MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina I.","family":"Dumitrascu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology Mayo Clinic Arizona  Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Campagna","sequence":"additional","affiliation":[{"name":"Department of Urology Mayo Clinic Arizona  Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology H. Lee Moffitt Cancer Center  Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Manley","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology H. Lee Moffitt Cancer Center  Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillippe E.","family":"Spiess","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology H. Lee Moffitt Cancer Center  Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-7200","authenticated-orcid":false,"given":"Roger","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology H. Lee Moffitt Cancer Center  Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-5913","authenticated-orcid":false,"given":"Mehrad","family":"Adibi","sequence":"additional","affiliation":[{"name":"Department of Urologic Oncology MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie S.","family":"Murray","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery University of Missouri  Columbia MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade J.","family":"Sexton","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology H. Lee Moffitt Cancer Center  Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell R.","family":"Humphreys","sequence":"additional","affiliation":[{"name":"Department of Urology Mayo Clinic Arizona  Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.05.042"},{"key":"e_1_2_6_3_1","first-page":"7369","article-title":"Critical analysis of 30 day complications following radical nephroureterectomy for upper tract urothelial carcinoma","volume":"21","author":"Lin YK","year":"2014","journal-title":"Can J Urol"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.06.015"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11066.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07535.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.07.014"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-015-1753-7"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30147-9"},{"key":"e_1_2_6_10_1","unstructured":"Administration USFaD.Full prescribing information: Jelmyto (miromycin) for pyelocalyceal solution 2021"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000003514"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.04.065"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4466"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2019.01.012"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.051"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002454"},{"key":"e_1_2_6_17_1","unstructured":"National Cancer I.Common terminology criteria for adverse events: (CTCAE) 2017"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.01.015"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24135"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1481395"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2019.11.22"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2017.12.009"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/end.2019.0750"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.05.066"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-010-0594-7"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2017.12.002"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.09.036"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.15925","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.15925","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.15925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:22:40Z","timestamp":1761733360000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.15925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1111\/bju.15925"],"URL":"https:\/\/doi.org\/10.1111\/bju.15925","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"2022-11-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}